Does the active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogate the CD4⁺ T cell-priming capacity of dendritic cells?
Our findings indicate a potential mechanism by which this compound may be effective in inhibiting FcR-driven CD4(+) T cell responses.
Age-dependent neutrophil RRs remain valid. Serial neutrophil values at 0, 12, and 24 hours plus blood culture and clinical evaluation can be used to discontinue antimicrobial therapy at 36-48 hours.